Sarepta Therapeutics Inc (SRPT) - Total Liabilities
Based on the latest financial reports, Sarepta Therapeutics Inc (SRPT) has total liabilities worth $1.66 Billion USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Sarepta Therapeutics Inc long-term investment intensity to see how much of total assets are deployed in long-term investments.
Sarepta Therapeutics Inc - Total Liabilities Trend (1995–2025)
This chart illustrates how Sarepta Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see how large is Sarepta Therapeutics Inc's balance sheet.
Sarepta Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Sarepta Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
UIE PLC
CO:UIE
|
Denmark | Dkr121.46 Million |
|
Changshu Tianyin Electromechan
SHE:300342
|
China | CN¥512.19 Million |
|
Interface Inc
NASDAQ:TILE
|
USA | $591.88 Million |
|
BWP Trust
AU:BWP
|
Australia | AU$1.08 Billion |
|
Super Retail Group Ltd
AU:SUL
|
Australia | AU$2.27 Billion |
|
Werner Enterprises Inc
NASDAQ:WERN
|
USA | $1.88 Billion |
|
IQM Quantum Computers Oyj American Depositary Shares
NASDAQ:IQMX
|
USA | $81.42 Million |
|
Dermapharm Holding SE
XETRA:DMP
|
Germany | €1.54 Billion |
Liability Composition Analysis (1995–2025)
This chart breaks down Sarepta Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Sarepta Therapeutics Inc (SRPT) balance sheet quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.42 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.52 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sarepta Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sarepta Therapeutics Inc (1995–2025)
The table below shows the annual total liabilities of Sarepta Therapeutics Inc from 1995 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $2.21 Billion | -9.29% |
| 2024-12-31 | $2.44 Billion | +1.26% |
| 2023-12-31 | $2.41 Billion | -12.33% |
| 2022-12-31 | $2.74 Billion | +23.58% |
| 2021-12-31 | $2.22 Billion | -0.13% |
| 2020-12-31 | $2.22 Billion | +121.27% |
| 2019-12-31 | $1.00 Billion | +64.75% |
| 2018-12-31 | $609.80 Million | +17.55% |
| 2017-12-31 | $518.75 Million | +493.44% |
| 2016-12-31 | $87.41 Million | +4.77% |
| 2015-12-31 | $83.44 Million | +76.10% |
| 2014-12-31 | $47.38 Million | +6.77% |
| 2013-12-31 | $44.38 Million | -45.43% |
| 2012-12-31 | $81.31 Million | +248.22% |
| 2011-12-31 | $23.35 Million | -52.14% |
| 2010-12-31 | $48.79 Million | +34.06% |
| 2009-12-31 | $36.40 Million | +271.25% |
| 2008-12-31 | $9.80 Million | -20.01% |
| 2007-12-31 | $12.26 Million | +288.98% |
| 2006-12-31 | $3.15 Million | +14.66% |
| 2005-12-31 | $2.75 Million | +22.15% |
| 2004-12-31 | $2.25 Million | -40.03% |
| 2003-12-31 | $3.75 Million | -26.77% |
| 2002-12-31 | $5.12 Million | +56.11% |
| 2001-12-31 | $3.28 Million | +90.45% |
| 2000-12-31 | $1.72 Million | +72.28% |
| 1999-12-31 | $1.00 Million | -16.67% |
| 1998-12-31 | $1.20 Million | +140.00% |
| 1997-12-31 | $500.00K | -85.29% |
| 1996-12-31 | $3.40 Million | +1033.33% |
| 1995-12-31 | $300.00K | -- |
About Sarepta Therapeutics Inc
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 ski… Read more